Lung Cancer
Wiley-Blackwell (Verlag)
978-1-118-46874-6 (ISBN)
The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.
Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.
Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever –featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.
This Fourth Edition of Lung Cancer:
Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer – vital for implementing screening, diagnosis, and prevention strategies
Presents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissues
Discusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatment
Offers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trials
With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.
Jack A. Roth, MD, F.A.C.S., is Professor and Bud Johnson Clinical Distinguished Chair in the Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director of the W.M. Keck Center of Innovative Cancer Therapies, and Chief of the Section of Thoracic Molecular Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. James D. Cox, MD, is Professor and Head of the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Waun Ki Hong, MD, D.M.Sc. (Hon.), is the American Cancer Society Professor and Samsung Distinguished University Chair in Cancer Medicine, as well as Professor and Head of the Division of Cancer Medicine and Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
Contributors, viii
Preface, xiii
1 Smoking Prevention and Cessation, 1
Alexander V. Prokhorov and Karen Suchanek Hudmon
2 Lung Cancer Susceptibility and Risk Assessment Models, 25
Xifeng Wu, Xia Pu, and Jie Lin
3 Molecular Profiling, 48
Lauren Averett Byers
4 Somatic Genome Alterations in Human Lung Cancers, 67
Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson
5 Serum Proteomic Biomarkers, 90
Mohamed Hassanein and David P. Carbone
6 Molecular Biology of Lung Preneoplasia, 110
Humam Kadara and Ignacio I. Wistuba
7 Detection and Treatment of Preneoplastic Lesions, 129
Rachel Jen and Stephen Lam
8 Pathology of Adenocarcinoma, 144
William D. Travis
9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158
Howard West
10 Radiology and Lung Cancer Screening, 176
Patricia de Groot and Reginald F. Munden
11 Imaging Lung Cancer, 191
Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus
12 Staging of the Mediastinum, 202
Mauricio Pipkin and Shaf Keshavjee
13 Management of the Solitary Pulmonary Nodule, 214
Min P. Kim
14 Minimally Invasive Resections for Lung Cancer, 224
Shanda H. Blackmon
15 Extended Resections for Lung Cancer, 236
Matthew A. Steliga and David C. Rice
16 Bronchoscopic Interventions for Lung Cancer, 253
Donald R. Lazarus and George A. Eapen
17 Primary Tracheal Tumors, 267
Francesco Sammartino and Paolo Macchiarini
18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278
Kathryn A. Gold
19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290
Christopher G. Azzoli and Katherine M.W. Pisters
20 Image-Guided Radiation Therapy, 309
Kenneth E. Rosenzweig and Sonal Sura
21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320
Puneeth Iyengar and Robert D. Timmerman
22 Proton Therapy, 338
Joe Y. Chang and James D. Cox
23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353
Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki
24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379
Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox
25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390
Steven H. Lin and Ritsuko U. Komaki
26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406
Kathryn F. Mileham, Edward S. Kim, and William N. William Jr
27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421
Erminia Massarelli
28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435
Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao
29 Immunologic Approaches to Lung Cancer Therapy, 454
Jay M. Lee, Steven M. Dubinett, and Sherven Sharma
30 Novel and Emerging Agents in NSCLC, 464
Anne S. Tsao and Jack A. Roth
31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479
Vassiliki A. Papadimitrakopoulou
32 Novel Statistical Models for NSCLC Clinical Trials, 488
J. Jack Lee and Caleb T. Chu
33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505
John V. Heymach and Tina Cascone
34 Anti-angiogenic Agents in Metastatic NSCLC, 527
Millie Das and Heather Wakelee
35 Targeting ALK Rearrangements, 541
Justin F. Gainor and Alice T. Shaw
36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557
Renata Ferrarotto and George R. Simon
37 Prognostic and Predictive Biomarker Signatures, 564
Johannes R. Kratz and David M. Jablons
38 Brain Metastasis from Lung Cancer, 572
Ritsuko U. Komaki and Amol J. Ghia
Index, 591
Color plate section between pages 146 and 147
| Verlagsort | Hoboken |
|---|---|
| Sprache | englisch |
| Maße | 193 x 244 mm |
| Gewicht | 1361 g |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| ISBN-10 | 1-118-46874-0 / 1118468740 |
| ISBN-13 | 978-1-118-46874-6 / 9781118468746 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
